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Background: Exploring the presence and role of human papillomavirus (HPV) in head and neck cancer (HNC) is a
necessary step to evaluate the potential impact of HPV prophylactic vaccines.
Objective: To assess the prevalence and oncogenic role of HPV in HNC in Senegal.
Methods: This is a multicenter cross-sectional study. Paraffin-embedded blocks of cases diagnosed with invasive
HNC between 2002 and 2010 were collected from 4 pathology laboratories in Senegal. Presence of HPV DNA was
determined by PCR and DEIA, and genotyping performed with LiPA25. Tubulin analysis was performed to assess
DNA quality. HPV DNA-positive cases were tested for p16INK4a expression.
Findings: A total of 117 cases were included in the analysis: 71% were men, mean age was 52 years old (SD ±18.3),
and 96% of cases were squamous cell carcinoma. Analysis was performed on 41 oral cavity tumors, 64 laryngeal
tumors, 5 oropharyngeal tumors and 7 pharyngeal tumors. Only four cases (3.4%; 95% CI = 0.9%-8.5%) harbored
HPV DNA. HPV types detected were HPV16, HPV35 and HPV45. However, among HPV-positive cases, none showed
p16INK4a overexpression.
Conclusion: Our findings indicate that HPV DNA prevalence in HNC in Senegal is very low, suggesting that HPV is
not a strong risk factor for these cancers. Additional larger studies are needed to confirm these findings and
explore other potential risk factors specific to the region.
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Head and neck cancer (HNC) is the eighth most common
cancer worldwide with approximately 650,000 new cases
and 350,000 deaths reported each year [1]. In addition to
alcohol and tobacco consumption, the latest evaluation on
the carcinogenicity of infections and cancer by the Inter-
national Agency for Research on Cancer established hu-
man papillomavirus (HPV) as a carcinogen of the oral
cavity and oropharynx [2].
In sub-Saharan Africa, knowledge on the role of HPV
in HNC is very limited. Actually, 84% of the existing* Correspondence: cathy.ndiaye@umontreal.ca
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reproduction in any medium, provided the orinformation on HPV and HNC is derived from studies in
Europe and North America [3]. The aim of our research
is to provide original data on the role of HPV in invasive
HNC in Senegal.Material and methods
This is a cross-sectional study designed and coordinated
by the Catalan Institute of Oncology in Barcelona and is
part of a large international study on HPV in HNC. Four
major centers in Dakar, Senegal, have provided consecu-
tive cases diagnosed with HNC from 2002 to 2010: Centre
Hospitalier Universitaire A. Le Dantec, Hôpital Principal
de Dakar, Hôpital Général de Grand Yoff and the path-
ology laboratory at Cheikh Anta Diop University. For each
specimen, after pathological confirmation of invasive diag-
nosis, a paraffin tissue section was treated with 250 μl of
freshly prepared Proteinase K solution to extract DNA.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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using 10 μl of a 1:10 dilution of the crude DNA extract in
a final reaction volume of 50 μl. The amplified PCR prod-
ucts were tested using a probe hybridization step with a
cocktail of conservative probes that can recognize around
54 mucosal HPV genotypes using a microtiter plate format
for the detection of HPV DNA through a DNA enzyme
immunoassay (DEIA) (produced by DDL, Voorburg, the
Netherlands). Optical densities (OD450) were read on a
microtiter plate reader and categorized as HPV DNA
negative, positive, or borderline. After PCR, 10 μl of the
DEIA HPV DNA positive amplimers were used to per-
form the reverse hybridization line probe assay (LiPA25)
(version 1: produced by DDL, Voorburg, the Netherlands).
The LiPA25 detects 25 high-risk and low-risk HPV types
(6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52,
53, 54, 56, 58, 59, 66, 68, 70, and 74). Additionally, amplifi-
cation of the human tubulin gene was performed to deter-
mine DNA quality of DEIA negative samples. In HPV
DNA-positive samples, p16INK4a overexpression was eval-
uated using CINtec histology kit (clone E6H4, mtm La-
boratories, Heidelberg, Germany) in order to verify the
potential causal role of HPV in positive cases. Overall
HPV detection percentages and 95% confidence intervals
(95% CI) were estimated. Data analyses were performed
with STATA 11.0. Ethical approval was obtained from the
Ministry of Health of Senegal.
Findings
Figure 1 displays the algorithm of sample selection for
analysis. The final number of cases included in the
study was 117: 41 oral cavity tumors, 64 laryngealFigure 1 Algorithm of head and neck cancer cases included in the stutumors (including 25 tumors whose site could not be
discerned between hypopharynx and larynx), 5 oro-
pharyngeal tumors and 7 pharyngeal tumors. Descrip-
tion of the cases is presented in Table 1. In this
study, 70.9% of cases were men and mean age was
52 years old (SD ±18.3). Squamous cell carcinoma
(SCC) represented 95.7% of cases.
The overall HPV prevalence was 3.4%; 95% CI = 0.9%-
8.5%. Table 2 shows the number of cases per subsite, the
distribution of HPV genotypes and results for p16INK4a ex-
pression. HPV DNA was detected in 4 carcinomas: one
gingival SCC (HPV35) and three laryngeal SCC (2 HPV45
and 1 HPV16). However, none of these cases showed
p16INK4a overexpression: 3 cases showed no p16INK4a stain-
ing and one HPV45 laryngeal cancer case showed focal
staining of less than 25% of cells with low-moderate
intensity.
Discussion
To our knowledge, this is the first study to explore the
presence of viral DNA and cellular protein expression in
head and neck tumors in West Africa. HPV DNA was
detected in 3.4% (95% CI = 0.9%-8.5%) of studied cases but
further analyses testing for p16INK4a expression suggested
that HPV was not involved in the oncogenic process of the
tumors. Expression of p16INK4a is strongly seen in HPV-
associated tumors but nearly absent in HPV-negative car-
cinomas [4] and increases in cases where HPV is
oncogenically involved due to the interaction of the viral
oncoprotein E7 with pRb [5].
Similar low HPV prevalences have been reported in the
African-American community in the USA. In a prospectivedy.
Table 1 HPV DNA detection in head and neck cancer
cases in Senegal by subjects’ characteristics




N % N % (95% CI)
Gender
Male 83 70.9 1 1.2 (0.0-6.5)
Female 34 29.1 3 8.8 (1.9-23.4)
Age at diagnosis (in years)
≤ 39 28 23.9 1 3.6 (0.0-18.3)
40-49 16 13.7 1 6.2 (0.2-30.2)
50-59 19 16.2 0 0.0 (0.0-17.6)b
≥ 60 49 41.9 2 4.1 (0.5-14.0)
Missing 5 4.3 0 0.0 (0.0-52.2)b
Period of diagnosis
2002 - 2008 53 45.3 3 5.7 (1.2-15.7)
2009 - 2010 64 54.7 1 1.6 (0.0-8.4)
Histological type
Squamous cell carcinoma 112 95.7 4 3.6 (1.0-8.9)
Adenocarcinoma 1 0.9 0 0.0 (0.0-97.5)b
Other diagnosesa 4 3.4 0 0.0 (0.0-60.2)b
Total 117 100 4 3.4 (0.9-8.5)
a Other diagnoses include 2 small cell neuroendocrine carcinomas and 2
adenoid cystic carcinomas.
b One-sided, 97.5% confidence interval.
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was 4% in black patients diagnosed with oropharyngeal
cancer versus 34% in white patients. Weinberger et al. [7]
found 0% HPV-active HNC in black patients compared to
21% in white patients after immunohistochemical testing
with p16INK4a. Both studies agree on significant ethnic and
biological disparities in HPV prevalence, after adjusting for
clinical and sociodemographic characteristics, and support
the validity of our study. Further studies are needed to elu-
cidate the mechanism of HPV clearance in African-
American and African populations, which share common
ancestral origins.
These findings are very different from what has been
reported previously in other regions of the world. In a sys-
tematic review by Kreimer et al. [3] compiling data on 60
studies focusing on HNSCC, HPV DNA was detected
overall in 26% of cases. Reported site-specific HPV preva-
lence was 23.5% (95% CI = 21.9-25.1%) in oral SCC, 35.6%
(95% CI = 32.6-38.7%) in oropharyngeal SCC and 24.0%
(95% CI = 21.8-26.3%) in laryngeal SCC [3]. The highest
detection rates were found in Asia, followed by the USA
and Nordic countries [3].
Low HPV prevalence in invasive HNC in Senegal sug-
gest that other established risk factors such as alcohol and
tobacco consumption may play a more significant etio-
logical role than HPV infection in HNC. However, theprevalence of tobacco use in Senegal is relatively low with
estimates of 19.9% in men and 1.3% in women [8]. Alcohol
consumption is also negligible, especially in women, since
Senegal is a predominantly Muslim country with 95% of
the population practicing this religion. Thus, the magni-
tude of the implication of these two classical risk factors in
the development of HNC is probably small given the so-
cial norms. Therefore, we hypothesize that environmental
factors and eating habits may contribute more importantly
to the development of HNC.
For example, indoor air pollution causes 6,300 deaths
each year in Senegal due to daily exposure to smoke from
open burning of wood and charcoal in homes [9]. More
than 80% of the households use either wood or charcoal as
cooking fuels in peri-urban and rural Senegal. Moreover,
burning incense to deodorize and heat the indoor is a
widely practiced cultural habit. The aforementioned are
potential risk factors for laryngeal and nasopharyngeal can-
cers as they expose individuals to smoke and dangerous
emissions of particles such as CO2 and CO [9]. According
to the WHO, 3.7% of the burden of disease in developing
countries can be attributed to indoor air pollution [9].
Another potential risk factor could be the consumption
of “ataya”, a strong and bitter hot tea comparable to “yerba
mate” in South America, which has been associated with an
increased risk of developing cancer of the oral cavity, larynx
and esophagus [10]. On average, at least three rounds of
“ataya” are served twice a day in Senegal. The fact that this
tea is drank at very hot temperature and consumed with
slurps can contribute to an increased risk of cancer.
Poor oral hygiene is another potential risk factor that has
been documented [11] and could play a non-negligible role
in Senegal. A study in 330 Senegalese university students
has shown poor dental health and the need to improve
prevention programs [12]. This study was conducted in an
educated cohort, which suggests that dental issues may be
worse in uneducated, low socio-economic populations with
limited access to dental care. Moreover, chewing of kola
nuts (Cola acuminate) has also been reported to increase
carcinogenesis potential of tobacco in smokers in Nigeria
by promoting palatal mucosa keratinization [13]. Con-
sumption of kola nuts is also widespread in Senegal.
Occupational exposure such as jobs in the construc-
tion, metal, textile, ceramic, logging, and food industries
has been associated with the development of laryngeal
cancer [14]. In Senegal, protective masks and safety rules
are not applied, as workplace safety regulations are not
reinforced mainly due to the fact that the informal sec-
tor provides most of the jobs. This reality puts workers
in a difficult predicament whereby they expose them-
selves to hazardous materials.
Our study has some methodological limitations. At sam-
ple collection stage, some cases were identified eligible for
the study but corresponding blocks were not found as they
Table 2 HPV DNA, HPV types and p16INK4a detection in HPV positive cases by head and neck cancer sites and subsites
HNC sites and subsites Cases tested for HPV HPV DNA positive HPV type p16INK4a overexpression
N % N % (95% CI)
Oral cavity
Lip 4 3.4 0 0.0
Gingiva 5 4.3 1 20.0 (0.5-71.6) HPV35 (N = 1) Negative
Floor of the mouth 1 0.9 0 0.0
Tongue 25 21.4 0 0.0
Hard palate 3 2.6 0 0.0
Palate unspecified 2 1.7 0 0.0
Oral cavity unspecified 1 0.9 0 0.0
Larynx
Epiglottis 2 1.7 0 0.0
Vocal cord 2 1.7 0 0.0
HPV45 (N = 2)
Larynx unspecified 35 29.9 3 8.6 (1.8-23.1) HPV16 (N = 1) Negative
Hypopharynx or larynx 25 21.4 0 0.0
Oropharynx
Tonsil 1 0.9 0 0.0
Oropharynx unspecified 4 3.4 0 0.0
Pharynx
Pharynx unspecified 1 0.9 0 0.0
Nasopharynx 6 5.1 0 0,0
Total 117 100.0 4 3.4 (0.9-8.5)
HNC: Head and neck cancer.
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ation. Additionally, several archival records were lost in one
of the main laboratories due to a fire. However, these issues
affected all cases regardless of patient characteristics or
diagnosis. Another major limitation is the lack of individual
data on risk factors: no information on patients besides
their gender, age and pathological information were avail-
able in the registries. Finally, the small sample size (n = 5)
for oropharyngeal tumors may have affected our positivity
rate. It is recognized that the highest associations of HPV
in HNC have been shown in the oropharynx, particularly in
the tonsils, with a positivity of 57% to 82% compared to
0.8% to 9% in other anatomic sites [15].
Our study has several strengths comprising the combined
use of highly sensitive assays for HPV DNA detection and a
marker of HPV related transforming process such as
p16INK4a expression. Additionally, we evaluated the quality
of our specimens by means of cellular tubulin detection and
subsequently excluded the HPV DNA negative and tubulin
negative cases from the statistical analyses. Lastly, all of the
study cases were selected from the main anatomy and path-
ology laboratories in Senegal. Thus, our cohort is represen-
tative of the target population as the vast majority of
patients are diagnosed in participant centers.Conclusion
In Senegal, HPV prevalence in HNC is very infrequent and
HPV infection is not associated with carcinogenesis. There-
fore, HPV prophylactic vaccines would not have any impact
on HNC incidence. Our findings need to be further vali-
dated with supplementary studies that include larger case
series and the assessment of region-specific risk factors.
Additional data will allow to close the gap of knowledge be-
tween Western countries and the sub-Saharan African re-
gion and to assist health authorities in implementing public
health strategies.
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